<i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients

Accumulating evidence has suggested that viral infection causes type 1 diabetes due to direct β-cell damage and the triggering of autoimmune reactivity to β cells. Here, we elucidated that the tyrosine kinase 2 <i>(Tyk2</i>) gene, encoding an interferon receptor signaling molecule, is re...

Full description

Bibliographic Details
Main Authors: Hitoe Mori, Hirokazu Takahashi, Keiichiro Mine, Ken Higashimoto, Kanako Inoue, Motoyasu Kojima, Shigetaka Kuroki, Takahisa Eguchi, Yasuhiro Ono, Sadataka Inuzuka, Hidenobu Soejima, Seiho Nagafuchi, Keizo Anzai
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Genes
Subjects:
n/a
Online Access:https://www.mdpi.com/2073-4425/12/3/400
id doaj-3beda35cd9dd41bba0e5a08b0ff08bac
record_format Article
spelling doaj-3beda35cd9dd41bba0e5a08b0ff08bac2021-03-12T00:03:36ZengMDPI AGGenes2073-44252021-03-011240040010.3390/genes12030400<i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes PatientsHitoe Mori0Hirokazu Takahashi1Keiichiro Mine2Ken Higashimoto3Kanako Inoue4Motoyasu Kojima5Shigetaka Kuroki6Takahisa Eguchi7Yasuhiro Ono8Sadataka Inuzuka9Hidenobu Soejima10Seiho Nagafuchi11Keizo Anzai12Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, JapanDivision of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, JapanDivision of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, JapanDivison of Molecular Genetics & Epigenetics, Department of Biomolecular Sciences, Faculty of Medicine, Saga 849-8501, JapanDivision of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, JapanDivision of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, JapanEguchi Hospital, Saga 845-0032, JapanEguchi Hospital, Saga 845-0032, JapanDepartment of Internal Medicine, Kouhokai Takagi Hospital, Fukuoka 831-0016, JapanInuzuka Hospital, Saga 849-1311, JapanDivison of Molecular Genetics & Epigenetics, Department of Biomolecular Sciences, Faculty of Medicine, Saga 849-8501, JapanDivision of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, JapanDivision of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, JapanAccumulating evidence has suggested that viral infection causes type 1 diabetes due to direct β-cell damage and the triggering of autoimmune reactivity to β cells. Here, we elucidated that the tyrosine kinase 2 <i>(Tyk2</i>) gene, encoding an interferon receptor signaling molecule, is responsible for virus-induced diabetes in mice, and its promoter variant confers a risk of type 1 diabetes in humans. This study investigated the relationship between a <i>TYK2</i> promoter variant <i>(TYK2PV)</i> and insulin secretion in type 2 diabetes patients. <i>TYK2PV</i> status was determined using direct DNA sequencing and its associations with fasting insulin, C-peptide, and homeostatic model assessment of insulin resistance (HOMA-IR) were evaluated in type 2 diabetes patients without sulfonylurea or insulin medication. Of the 172 patients assessed, 18 (10.5%) showed <i>TYK2PV</i>-positivity. Their body mass index (BMI) was significantly lower than in those without the variant (23.4 vs. 25.4 kg/m<sup>2</sup>, <i>p</i> = 0.025). Fasting insulin (3.9 vs. 6.2 μIU/mL, <i>p</i> = 0.007), C-peptide (1.37 vs. 1.76 ng/mL, <i>p</i> = 0.008), and HOMA-IR (1.39 vs. 2.05, <i>p</i> = 0.006) were lower in those with than in those without the variant. Multivariable analysis identified that <i>TYK2PV</i> was associated with fasting insulin ≤ 5 μIU/mL (odds ratio (OR) 3.63, <i>p</i> = 0.025) and C-peptide ≤ 1.0 ng/mL (OR 3.61, <i>p</i> = 0.028), and also lower insulin resistance (HOMA-IR ≤ 2.5; OR 8.60, <i>p</i> = 0.042). <i>TYK2PV</i> is associated with impaired insulin secretion and low insulin resistance in type 2 diabetes. Type 2 diabetes patients with <i>TYK2PV</i> should be carefully followed in order to receive the appropriate treatment including insulin injections.https://www.mdpi.com/2073-4425/12/3/400n/a
collection DOAJ
language English
format Article
sources DOAJ
author Hitoe Mori
Hirokazu Takahashi
Keiichiro Mine
Ken Higashimoto
Kanako Inoue
Motoyasu Kojima
Shigetaka Kuroki
Takahisa Eguchi
Yasuhiro Ono
Sadataka Inuzuka
Hidenobu Soejima
Seiho Nagafuchi
Keizo Anzai
spellingShingle Hitoe Mori
Hirokazu Takahashi
Keiichiro Mine
Ken Higashimoto
Kanako Inoue
Motoyasu Kojima
Shigetaka Kuroki
Takahisa Eguchi
Yasuhiro Ono
Sadataka Inuzuka
Hidenobu Soejima
Seiho Nagafuchi
Keizo Anzai
<i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
Genes
n/a
author_facet Hitoe Mori
Hirokazu Takahashi
Keiichiro Mine
Ken Higashimoto
Kanako Inoue
Motoyasu Kojima
Shigetaka Kuroki
Takahisa Eguchi
Yasuhiro Ono
Sadataka Inuzuka
Hidenobu Soejima
Seiho Nagafuchi
Keizo Anzai
author_sort Hitoe Mori
title <i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
title_short <i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
title_full <i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
title_fullStr <i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
title_full_unstemmed <i>TYK2</i> Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
title_sort <i>tyk2</i> promoter variant is associated with impaired insulin secretion and lower insulin resistance in japanese type 2 diabetes patients
publisher MDPI AG
series Genes
issn 2073-4425
publishDate 2021-03-01
description Accumulating evidence has suggested that viral infection causes type 1 diabetes due to direct β-cell damage and the triggering of autoimmune reactivity to β cells. Here, we elucidated that the tyrosine kinase 2 <i>(Tyk2</i>) gene, encoding an interferon receptor signaling molecule, is responsible for virus-induced diabetes in mice, and its promoter variant confers a risk of type 1 diabetes in humans. This study investigated the relationship between a <i>TYK2</i> promoter variant <i>(TYK2PV)</i> and insulin secretion in type 2 diabetes patients. <i>TYK2PV</i> status was determined using direct DNA sequencing and its associations with fasting insulin, C-peptide, and homeostatic model assessment of insulin resistance (HOMA-IR) were evaluated in type 2 diabetes patients without sulfonylurea or insulin medication. Of the 172 patients assessed, 18 (10.5%) showed <i>TYK2PV</i>-positivity. Their body mass index (BMI) was significantly lower than in those without the variant (23.4 vs. 25.4 kg/m<sup>2</sup>, <i>p</i> = 0.025). Fasting insulin (3.9 vs. 6.2 μIU/mL, <i>p</i> = 0.007), C-peptide (1.37 vs. 1.76 ng/mL, <i>p</i> = 0.008), and HOMA-IR (1.39 vs. 2.05, <i>p</i> = 0.006) were lower in those with than in those without the variant. Multivariable analysis identified that <i>TYK2PV</i> was associated with fasting insulin ≤ 5 μIU/mL (odds ratio (OR) 3.63, <i>p</i> = 0.025) and C-peptide ≤ 1.0 ng/mL (OR 3.61, <i>p</i> = 0.028), and also lower insulin resistance (HOMA-IR ≤ 2.5; OR 8.60, <i>p</i> = 0.042). <i>TYK2PV</i> is associated with impaired insulin secretion and low insulin resistance in type 2 diabetes. Type 2 diabetes patients with <i>TYK2PV</i> should be carefully followed in order to receive the appropriate treatment including insulin injections.
topic n/a
url https://www.mdpi.com/2073-4425/12/3/400
work_keys_str_mv AT hitoemori ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT hirokazutakahashi ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT keiichiromine ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT kenhigashimoto ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT kanakoinoue ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT motoyasukojima ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT shigetakakuroki ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT takahisaeguchi ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT yasuhiroono ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT sadatakainuzuka ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT hidenobusoejima ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT seihonagafuchi ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
AT keizoanzai ityk2ipromotervariantisassociatedwithimpairedinsulinsecretionandlowerinsulinresistanceinjapanesetype2diabetespatients
_version_ 1724223366968115200